社区
首页
集团介绍
社区
资讯
行情
学堂
TigerGPT
登录
注册
Syww
IP属地：未知
+关注
帖子 · 253
帖子 · 253
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
Syww
Syww
·
2021-12-21
[Strong]
非常抱歉，此主贴已删除
看
1,497
回复
1
点赞
2
编组 21备份 2
分享
举报
Syww
Syww
·
2021-12-21
[Strong] [Strong]
非常抱歉，此主贴已删除
看
1,424
回复
评论
点赞
3
编组 21备份 2
分享
举报
Syww
Syww
·
2021-12-19
[Strong] [Strong]
Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade
The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5
Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade
看
1,091
回复
评论
点赞
6
编组 21备份 2
分享
举报
Syww
Syww
·
2021-12-19
[Strong] [Strong]
非常抱歉，此主贴已删除
看
1,461
回复
评论
点赞
3
编组 21备份 2
分享
举报
Syww
Syww
·
2021-12-18
[Strong] [Strong]
非常抱歉，此主贴已删除
看
1,427
回复
评论
点赞
4
编组 21备份 2
分享
举报
Syww
Syww
·
2021-12-18
[Strong] [Strong]
非常抱歉，此主贴已删除
看
1,448
回复
评论
点赞
3
编组 21备份 2
分享
举报
Syww
Syww
·
2021-12-17
[Strong] [Strong]
Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron
Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity a
Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron
看
1,269
回复
1
点赞
4
编组 21备份 2
分享
举报
Syww
Syww
·
2021-12-16
[Strong] [Strong]
SEC Floats Rules to Shore Up Money Markets, Curb Insider Trading
Wall Street regulators moved forward on four plans, advancing far-reaching agenda under Chairman Gar
SEC Floats Rules to Shore Up Money Markets, Curb Insider Trading
看
1,318
回复
1
点赞
2
编组 21备份 2
分享
举报
Syww
Syww
·
2021-12-16
[Strong] [Strong]
非常抱歉，此主贴已删除
看
1,579
回复
1
点赞
4
编组 21备份 2
分享
举报
Syww
Syww
·
2021-12-15
[Strong]
Leslie's slips on secondary offering of 12.50M shares
Leslie's (NASDAQ:LESL) has announced a secondary offering of 12.50M shares of its common stock by se
Leslie's slips on secondary offering of 12.50M shares
看
1,044
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4087953623473280","uuid":"4087953623473280","gmtCreate":1624850679049,"gmtModify":1634379872021,"name":"Syww","pinyin":"syww","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/eb83576edbcfb98efcb33d606f168221","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":20,"headSize":425,"tweetSize":253,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":693596669,"gmtCreate":1640047422606,"gmtModify":1640047422858,"author":{"id":"4087953623473280","authorId":"4087953623473280","name":"Syww","avatar":"https://static.tigerbbs.com/eb83576edbcfb98efcb33d606f168221","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087953623473280","authorIdStr":"4087953623473280"},"themes":[],"htmlText":"[Strong] ","listText":"[Strong] ","text":"[Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693596669","repostId":"1198736123","repostType":4,"isVote":1,"tweetType":1,"viewCount":1497,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693598470,"gmtCreate":1640047374446,"gmtModify":1640047374739,"author":{"id":"4087953623473280","authorId":"4087953623473280","name":"Syww","avatar":"https://static.tigerbbs.com/eb83576edbcfb98efcb33d606f168221","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087953623473280","authorIdStr":"4087953623473280"},"themes":[],"htmlText":"[Strong] [Strong] ","listText":"[Strong] [Strong] ","text":"[Strong] [Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693598470","repostId":"1102941409","repostType":4,"isVote":1,"tweetType":1,"viewCount":1424,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699712033,"gmtCreate":1639893865220,"gmtModify":1639893865468,"author":{"id":"4087953623473280","authorId":"4087953623473280","name":"Syww","avatar":"https://static.tigerbbs.com/eb83576edbcfb98efcb33d606f168221","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087953623473280","authorIdStr":"4087953623473280"},"themes":[],"htmlText":"[Strong] [Strong] ","listText":"[Strong] [Strong] ","text":"[Strong] [Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699712033","repostId":"1122414343","repostType":4,"repost":{"id":"1122414343","kind":"news","pubTimestamp":1639884070,"share":"https://www.laohu8.com/m/news/1122414343?lang=&edition=full","pubTime":"2021-12-19 11:21","market":"us","language":"en","title":"Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade","url":"https://stock-news.laohu8.com/highlight/detail?id=1122414343","media":"Seeking Alpha","summary":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5","content":"<p>The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.</p>\n<p>Among stocks with more than $2B market capitalization and 100K average daily volume over the past week, <a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals </a> dominated with a ~83.8% rise after <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. <a href=\"https://laohu8.com/S/CERN\">Cerner </a> also joined the M&A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from <a href=\"https://laohu8.com/S/ORCL\">Oracle </a> for the electronic-medical-records company.</p>\n<p>Vaccine developer, <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.</p>\n<p><a href=\"https://laohu8.com/S/BHVN\">Biohaven Pharmaceutical </a> posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, <a href=\"https://laohu8.com/S/ROIV\">Roivant Sciences </a> added ~22.6%.</p>\n<p>Notable gainer: <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the <a href=\"https://laohu8.com/S/NWY\">New York</a>-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.</p>\n<p>Among worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.</p>\n<p>Last week’s best performer, <a href=\"https://laohu8.com/S/BHG\">Bright Health Group</a>, crashed ~13.1%, hurt by the sole Sell rating issued by <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> even as the investment bank kicked off its coverage on managed care with largely positive views.</p>\n<p>Allogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic <a href=\"https://laohu8.com/S/00699\">CAR</a> T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax, Vir among healthcare gainers, Pfizer posts best rally in a decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-19 11:21 GMT+8 <a href=https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the ...</p>\n\n<a href=\"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","ARNA":"阿里那","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4007":"制药","CERN":"美国塞纳","PFE":"辉瑞","ORCL":"甲骨文"},"source_url":"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122414343","content_text":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.\nAmong stocks with more than $2B market capitalization and 100K average daily volume over the past week, Arena Pharmaceuticals dominated with a ~83.8% rise after Pfizer agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. Cerner also joined the M&A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from Oracle for the electronic-medical-records company.\nVaccine developer, Novavax jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.\nBiohaven Pharmaceutical posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, Roivant Sciences added ~22.6%.\nNotable gainer: Pfizer (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the New York-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.\nAmong worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.\nLast week’s best performer, Bright Health Group, crashed ~13.1%, hurt by the sole Sell rating issued by Goldman Sachs even as the investment bank kicked off its coverage on managed care with largely positive views.\nAllogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic CAR T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1091,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699716416,"gmtCreate":1639893814350,"gmtModify":1639893814605,"author":{"id":"4087953623473280","authorId":"4087953623473280","name":"Syww","avatar":"https://static.tigerbbs.com/eb83576edbcfb98efcb33d606f168221","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087953623473280","authorIdStr":"4087953623473280"},"themes":[],"htmlText":"[Strong] [Strong] ","listText":"[Strong] [Strong] ","text":"[Strong] [Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699716416","repostId":"2192035909","repostType":4,"isVote":1,"tweetType":1,"viewCount":1461,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699854083,"gmtCreate":1639785114482,"gmtModify":1639785114773,"author":{"id":"4087953623473280","authorId":"4087953623473280","name":"Syww","avatar":"https://static.tigerbbs.com/eb83576edbcfb98efcb33d606f168221","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087953623473280","authorIdStr":"4087953623473280"},"themes":[],"htmlText":"[Strong] [Strong] ","listText":"[Strong] [Strong] ","text":"[Strong] [Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699854083","repostId":"1113352768","repostType":4,"isVote":1,"tweetType":1,"viewCount":1427,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699855169,"gmtCreate":1639785072058,"gmtModify":1639785072311,"author":{"id":"4087953623473280","authorId":"4087953623473280","name":"Syww","avatar":"https://static.tigerbbs.com/eb83576edbcfb98efcb33d606f168221","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087953623473280","authorIdStr":"4087953623473280"},"themes":[],"htmlText":"[Strong] [Strong] ","listText":"[Strong] [Strong] ","text":"[Strong] [Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699855169","repostId":"2192597562","repostType":4,"isVote":1,"tweetType":1,"viewCount":1448,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690588662,"gmtCreate":1639692379013,"gmtModify":1639692379258,"author":{"id":"4087953623473280","authorId":"4087953623473280","name":"Syww","avatar":"https://static.tigerbbs.com/eb83576edbcfb98efcb33d606f168221","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087953623473280","authorIdStr":"4087953623473280"},"themes":[],"htmlText":"[Strong] [Strong] ","listText":"[Strong] [Strong] ","text":"[Strong] [Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/690588662","repostId":"1108384523","repostType":4,"repost":{"id":"1108384523","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639667369,"share":"https://www.laohu8.com/m/news/1108384523?lang=&edition=full","pubTime":"2021-12-16 23:09","market":"us","language":"en","title":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1108384523","media":"Tiger Newspress","summary":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity a","content":"<p>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.<img src=\"https://static.tigerbbs.com/07fe5a6b831322eef2c479861ad70527\" tg-width=\"766\" tg-height=\"563\" width=\"100%\" height=\"auto\">The company announced new preclinical data, published to the preprint server bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529). </p>\n<p>A significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals. </p>\n<p>Researchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved). </p>\n<p>Data demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with GlaxoSmithKline plc (NYSE: GSK), retained their in vitro neutralizing activity against omicron.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-16 23:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.<img src=\"https://static.tigerbbs.com/07fe5a6b831322eef2c479861ad70527\" tg-width=\"766\" tg-height=\"563\" width=\"100%\" height=\"auto\">The company announced new preclinical data, published to the preprint server bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529). </p>\n<p>A significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals. </p>\n<p>Researchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved). </p>\n<p>Data demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with GlaxoSmithKline plc (NYSE: GSK), retained their in vitro neutralizing activity against omicron.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108384523","content_text":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.The company announced new preclinical data, published to the preprint server bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529). \nA significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals. \nResearchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved). \nData demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with GlaxoSmithKline plc (NYSE: GSK), retained their in vitro neutralizing activity against omicron.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1269,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607777381,"gmtCreate":1639610691645,"gmtModify":1639610691966,"author":{"id":"4087953623473280","authorId":"4087953623473280","name":"Syww","avatar":"https://static.tigerbbs.com/eb83576edbcfb98efcb33d606f168221","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087953623473280","authorIdStr":"4087953623473280"},"themes":[],"htmlText":"[Strong] [Strong] ","listText":"[Strong] [Strong] ","text":"[Strong] [Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/607777381","repostId":"1120514133","repostType":4,"repost":{"id":"1120514133","kind":"news","pubTimestamp":1639610400,"share":"https://www.laohu8.com/m/news/1120514133?lang=&edition=full","pubTime":"2021-12-16 07:20","market":"us","language":"en","title":"SEC Floats Rules to Shore Up Money Markets, Curb Insider Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1120514133","media":"The Wall Street Journal","summary":"Wall Street regulators moved forward on four plans, advancing far-reaching agenda under Chairman Gar","content":"<p>Wall Street regulators moved forward on four plans, advancing far-reaching agenda under Chairman Gary Gensler</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b3fe6cee065b92f8814d20c6ac8b4740\" tg-width=\"1290\" tg-height=\"859\" width=\"100%\" height=\"auto\"><span>The SEC under Chairman Gary Gensler plans to offer changes to make the most-vulnerable subset of money-market funds less susceptible to investor runs.</span></p>\n<p>WASHINGTON—The Securities and Exchange Commission issued a raft of proposals Wednesday including measures aimed at shoring up money-market funds and curbing executives’ ability to trade their own companies’ stock.</p>\n<p>The proposals, some of which surprised Wall Street executives with their scope, indicate that Chairman Gary Gensler is moving quickly to enact a policy agenda that observers have called the SEC’s most ambitious in decades. That stands in contrast to other financial regulators, for which President Biden has yet to fill key positions, and saw a nominee withdraw amid Senate skepticism during confirmation.</p>\n<p>With a thin majority in Congress, Democrats are leaning on Mr. Gensler to advance progressive priorities such as fighting climate change and curbing the power of big business. The SEC’s authority to write rules for asset managers, publicly traded companies and the stock market provides powerful, if sometimes roundabout, tools for achieving such goals.</p>\n<p>The proposals “will go a long way toward increasing corporate transparency and accountability,” Sen. Sherrod Brown (D., Ohio), chairman of the Senate Banking Committee, said, praising enhanced disclosures around stock buybacks. “The first step to workers getting their fair share is learning just how much corporate executives are spending on themselves.”</p>\n<p>Mr. Gensler’s agenda reflects political divisions. Three of the four proposals garnered party-line votes from the SEC’s five commissioners. Republicans Hester Peirce and Elad Roisman supported only a plan to tighten rules on how and when corporate insiders can sell their companies’ stocks. The agency is independent of the Biden administration.</p>\n<p>The other proposals “are a partisan overreach that will likely diminish investment opportunities, economic growth and capital formation,” Sen. Pat Toomey (R., Penn.), the top Republican on the Senate Banking Committee, said.</p>\n<p>Two of the proposals put forward Wednesday seek to make the financial system more stable by reducing panicked investors’ tendency to flee money-market funds and by regulating opaque derivatives known as “swaps.”The other two rules would seek to enhance fairness and transparency in the stock market. They would introduce new restrictions on corporate executives’ trading and heighten disclosure requirements around share buybacks by publicly traded companies.</p>\n<p>The new rules for money-market mutual funds aim to prevent episodes that occurred during the past two recessions, in 2008 and 2020, when the Federal Reserve was forced to backstop the funds after they were hit with a wave of redemption requests that caused credit markets to seize up.</p>\n<p>Money markets are typically used by corporate treasurers, pension funds and millions of individual investors as a safe place to park cash and earn a higher return than they could obtain in a bank account. They provide companies with liquidity for short-term loans, called “commercial paper,” to cover immediate expenses like payroll.</p>\n<p>But money-market funds aren’t regulated like banks, which must meet minimum capital requirements and offer deposit insurance. Regulators say this makes them more susceptible to runs when markets are under severe stress, creating broader risks to the financial system.</p>\n<p>“This is about resiliency,” Mr. Gensler said in an interview, noting that Americans have roughly $5 trillion invested in money markets. “Though there have been reforms in 2010 and 2014, we found again in 2020 some instability…with the dash for cash.”</p>\n<p>The SEC’s proposed changes include a measure called “swing pricing” that firms including BlackRock Inc. and Federated Hermes Inc. have warned could destroy a subset of the industry that holds short short-term corporate debt and caters to institutional investors. The measure would require these funds to adopt policies for adjusting their share prices by a “swing factor” on days when they have net redemptions. The factor would be determined by transaction costs and the market impact of selling a slice of the fund’s portfolio.</p>\n<p>The goal is to protect investors who remain in the fund from dilution by investors who redeem their shares, Mr. Gensler said.</p>\n<p>The SEC’s timing caught money-market fund managers off guard, said John Tobin, investment chief at Dreyfus Cash Investment Strategies, which oversees $350 billion in money funds. Many didn’t expect to see the new proposed rules until next spring, he said.</p>\n<p>The swing-pricing proposal is likely to draw universal industry opposition, said Mr. Tobin, whose business is a unit of Bank of New York Mellon Corp.He said the rule would create operational challenges and could encourage institutional investors to head for the exits before a fund executes any swing-price decision.</p>\n<p>“It’s definitely a shot across the bow,” he said. “This is a watershed moment.”</p>\n<p>The SEC also proposed significant restrictions on arrangements, known as 10b5-5 plans, by which corporate officers and directors schedule stock trades ahead of time to avoid running afoul of insider-trading rules. Among other changes, the agency would require executives to wait 120 days before buying or selling their employer’s stock after setting up or modifying the plans.</p>\n<p>That proposal follows academic research suggesting the arrangements are being abused as company leaders cash in at historic levels on their companies’ shares.</p>\n<p>“The core issue is that these insiders regularly have material information that the public doesn’t have,” Mr. Gensler said in a statement. Wednesday’s proposed changes seek to ensure their stock trading is done “in a way that’s fair to the marketplace,” he added.</p>\n<p>Commissioners also voted 3-2 along party lines to propose increased disclosures around public companies’ stock buybacks, which are also hitting records this year.</p>\n<p>Repurchases support stock prices by reducing the number of shares outstanding in a company, lifting the firm’s earnings per share. Like dividends, they enable companies to return cash to investors. But critics, including many Democrats, say buybacks give executives who are partly paid in equity or options a roundabout way of boosting their own compensation, at the expense of workers’ wages or productive investments.</p>\n<p>The SEC’s proposal would require stock-buyback disclosures to be more detailed and more frequent. Rather than disclosing monthly aggregate share repurchases once a quarter, companies would have to report buybacks on the next business day. They would also have to indicate whether any executives bought or sold shares within 10 business days of a buyback program’s announcement.</p>\n<p>“Companies may determine to allocate capital towards share repurchases for a number of different reasons,” Democratic SEC Commissioner Allison Lee said. “But one of those reasons should not be for the opportunistic, short-term benefit of executives.”</p>\n<p>The SEC’s chief economist, Jessica Wachter, said during the meeting that the costs of complying with the increased disclosure requirements might discourage some companies from buying back stock. Ms. Peirce and Mr. Roisman issued strong dissents against the rule.</p>\n<p>“Say ‘dividend,’ and nobody gets angry, but say ‘share buyback,’ and the rage boils over,” Ms. Peirce said. “Today’s proposal channels some of that rage against repurchases in a way that only a regulator can: through painfully granular, unnecessarily frequent disclosure obligations.”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SEC Floats Rules to Shore Up Money Markets, Curb Insider Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSEC Floats Rules to Shore Up Money Markets, Curb Insider Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-16 07:20 GMT+8 <a href=https://www.wsj.com/articles/sec-floats-money-market-fund-rules-to-deter-investor-runs-11639579017?mod=hp_lead_pos3><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street regulators moved forward on four plans, advancing far-reaching agenda under Chairman Gary Gensler\nThe SEC under Chairman Gary Gensler plans to offer changes to make the most-vulnerable ...</p>\n\n<a href=\"https://www.wsj.com/articles/sec-floats-money-market-fund-rules-to-deter-investor-runs-11639579017?mod=hp_lead_pos3\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"https://www.wsj.com/articles/sec-floats-money-market-fund-rules-to-deter-investor-runs-11639579017?mod=hp_lead_pos3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120514133","content_text":"Wall Street regulators moved forward on four plans, advancing far-reaching agenda under Chairman Gary Gensler\nThe SEC under Chairman Gary Gensler plans to offer changes to make the most-vulnerable subset of money-market funds less susceptible to investor runs.\nWASHINGTON—The Securities and Exchange Commission issued a raft of proposals Wednesday including measures aimed at shoring up money-market funds and curbing executives’ ability to trade their own companies’ stock.\nThe proposals, some of which surprised Wall Street executives with their scope, indicate that Chairman Gary Gensler is moving quickly to enact a policy agenda that observers have called the SEC’s most ambitious in decades. That stands in contrast to other financial regulators, for which President Biden has yet to fill key positions, and saw a nominee withdraw amid Senate skepticism during confirmation.\nWith a thin majority in Congress, Democrats are leaning on Mr. Gensler to advance progressive priorities such as fighting climate change and curbing the power of big business. The SEC’s authority to write rules for asset managers, publicly traded companies and the stock market provides powerful, if sometimes roundabout, tools for achieving such goals.\nThe proposals “will go a long way toward increasing corporate transparency and accountability,” Sen. Sherrod Brown (D., Ohio), chairman of the Senate Banking Committee, said, praising enhanced disclosures around stock buybacks. “The first step to workers getting their fair share is learning just how much corporate executives are spending on themselves.”\nMr. Gensler’s agenda reflects political divisions. Three of the four proposals garnered party-line votes from the SEC’s five commissioners. Republicans Hester Peirce and Elad Roisman supported only a plan to tighten rules on how and when corporate insiders can sell their companies’ stocks. The agency is independent of the Biden administration.\nThe other proposals “are a partisan overreach that will likely diminish investment opportunities, economic growth and capital formation,” Sen. Pat Toomey (R., Penn.), the top Republican on the Senate Banking Committee, said.\nTwo of the proposals put forward Wednesday seek to make the financial system more stable by reducing panicked investors’ tendency to flee money-market funds and by regulating opaque derivatives known as “swaps.”The other two rules would seek to enhance fairness and transparency in the stock market. They would introduce new restrictions on corporate executives’ trading and heighten disclosure requirements around share buybacks by publicly traded companies.\nThe new rules for money-market mutual funds aim to prevent episodes that occurred during the past two recessions, in 2008 and 2020, when the Federal Reserve was forced to backstop the funds after they were hit with a wave of redemption requests that caused credit markets to seize up.\nMoney markets are typically used by corporate treasurers, pension funds and millions of individual investors as a safe place to park cash and earn a higher return than they could obtain in a bank account. They provide companies with liquidity for short-term loans, called “commercial paper,” to cover immediate expenses like payroll.\nBut money-market funds aren’t regulated like banks, which must meet minimum capital requirements and offer deposit insurance. Regulators say this makes them more susceptible to runs when markets are under severe stress, creating broader risks to the financial system.\n“This is about resiliency,” Mr. Gensler said in an interview, noting that Americans have roughly $5 trillion invested in money markets. “Though there have been reforms in 2010 and 2014, we found again in 2020 some instability…with the dash for cash.”\nThe SEC’s proposed changes include a measure called “swing pricing” that firms including BlackRock Inc. and Federated Hermes Inc. have warned could destroy a subset of the industry that holds short short-term corporate debt and caters to institutional investors. The measure would require these funds to adopt policies for adjusting their share prices by a “swing factor” on days when they have net redemptions. The factor would be determined by transaction costs and the market impact of selling a slice of the fund’s portfolio.\nThe goal is to protect investors who remain in the fund from dilution by investors who redeem their shares, Mr. Gensler said.\nThe SEC’s timing caught money-market fund managers off guard, said John Tobin, investment chief at Dreyfus Cash Investment Strategies, which oversees $350 billion in money funds. Many didn’t expect to see the new proposed rules until next spring, he said.\nThe swing-pricing proposal is likely to draw universal industry opposition, said Mr. Tobin, whose business is a unit of Bank of New York Mellon Corp.He said the rule would create operational challenges and could encourage institutional investors to head for the exits before a fund executes any swing-price decision.\n“It’s definitely a shot across the bow,” he said. “This is a watershed moment.”\nThe SEC also proposed significant restrictions on arrangements, known as 10b5-5 plans, by which corporate officers and directors schedule stock trades ahead of time to avoid running afoul of insider-trading rules. Among other changes, the agency would require executives to wait 120 days before buying or selling their employer’s stock after setting up or modifying the plans.\nThat proposal follows academic research suggesting the arrangements are being abused as company leaders cash in at historic levels on their companies’ shares.\n“The core issue is that these insiders regularly have material information that the public doesn’t have,” Mr. Gensler said in a statement. Wednesday’s proposed changes seek to ensure their stock trading is done “in a way that’s fair to the marketplace,” he added.\nCommissioners also voted 3-2 along party lines to propose increased disclosures around public companies’ stock buybacks, which are also hitting records this year.\nRepurchases support stock prices by reducing the number of shares outstanding in a company, lifting the firm’s earnings per share. Like dividends, they enable companies to return cash to investors. But critics, including many Democrats, say buybacks give executives who are partly paid in equity or options a roundabout way of boosting their own compensation, at the expense of workers’ wages or productive investments.\nThe SEC’s proposal would require stock-buyback disclosures to be more detailed and more frequent. Rather than disclosing monthly aggregate share repurchases once a quarter, companies would have to report buybacks on the next business day. They would also have to indicate whether any executives bought or sold shares within 10 business days of a buyback program’s announcement.\n“Companies may determine to allocate capital towards share repurchases for a number of different reasons,” Democratic SEC Commissioner Allison Lee said. “But one of those reasons should not be for the opportunistic, short-term benefit of executives.”\nThe SEC’s chief economist, Jessica Wachter, said during the meeting that the costs of complying with the increased disclosure requirements might discourage some companies from buying back stock. Ms. Peirce and Mr. Roisman issued strong dissents against the rule.\n“Say ‘dividend,’ and nobody gets angry, but say ‘share buyback,’ and the rage boils over,” Ms. Peirce said. “Today’s proposal channels some of that rage against repurchases in a way that only a regulator can: through painfully granular, unnecessarily frequent disclosure obligations.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":1318,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607774456,"gmtCreate":1639610679749,"gmtModify":1639610679997,"author":{"id":"4087953623473280","authorId":"4087953623473280","name":"Syww","avatar":"https://static.tigerbbs.com/eb83576edbcfb98efcb33d606f168221","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087953623473280","authorIdStr":"4087953623473280"},"themes":[],"htmlText":"[Strong] [Strong] ","listText":"[Strong] [Strong] ","text":"[Strong] [Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/607774456","repostId":"2191994940","repostType":4,"isVote":1,"tweetType":1,"viewCount":1579,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607858697,"gmtCreate":1639527402229,"gmtModify":1639527402501,"author":{"id":"4087953623473280","authorId":"4087953623473280","name":"Syww","avatar":"https://static.tigerbbs.com/eb83576edbcfb98efcb33d606f168221","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087953623473280","authorIdStr":"4087953623473280"},"themes":[],"htmlText":"[Strong] ","listText":"[Strong] ","text":"[Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607858697","repostId":"1132792815","repostType":4,"repost":{"id":"1132792815","kind":"news","pubTimestamp":1639525643,"share":"https://www.laohu8.com/m/news/1132792815?lang=&edition=full","pubTime":"2021-12-15 07:47","market":"us","language":"en","title":"Leslie's slips on secondary offering of 12.50M shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1132792815","media":"seekingalpha","summary":"Leslie's (NASDAQ:LESL) has announced a secondary offering of 12.50M shares of its common stock by se","content":"<p></p>\n<p>Leslie's (NASDAQ:LESL) has announced a secondary offering of 12.50M shares of its common stock by selling stockholders.</p>\n<p>Underwriters will be granted a 30-day option to purchase up to an additional 1,875,000 shares of common stock.</p>\n<p>All proceeds from the sale will go to the selling stockholders.</p>\n<p>Leslie's also announced a share repurchase agreement, under which it plans to buyback 7.5M shares of its common stock from the selling stockholders. The repurchase is expected to be consummated concurrently with the closing of the offering.</p>\n<p>LESL is trading down 1.90% after-hours</p>\n<p>Earlier this month, Leslie's announced a $300M share repurchase program; initiated FY22 guidance</p>","source":"lsy1638401102509","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Leslie's slips on secondary offering of 12.50M shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLeslie's slips on secondary offering of 12.50M shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-15 07:47 GMT+8 <a href=https://seekingalpha.com/news/3780158-leslies-slips-on-secondary-offering-of-1250m-shares><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Leslie's (NASDAQ:LESL) has announced a secondary offering of 12.50M shares of its common stock by selling stockholders.\nUnderwriters will be granted a 30-day option to purchase up to an additional 1,...</p>\n\n<a href=\"https://seekingalpha.com/news/3780158-leslies-slips-on-secondary-offering-of-1250m-shares\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LESL":"Leslie's, Inc."},"source_url":"https://seekingalpha.com/news/3780158-leslies-slips-on-secondary-offering-of-1250m-shares","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1132792815","content_text":"Leslie's (NASDAQ:LESL) has announced a secondary offering of 12.50M shares of its common stock by selling stockholders.\nUnderwriters will be granted a 30-day option to purchase up to an additional 1,875,000 shares of common stock.\nAll proceeds from the sale will go to the selling stockholders.\nLeslie's also announced a share repurchase agreement, under which it plans to buyback 7.5M shares of its common stock from the selling stockholders. The repurchase is expected to be consummated concurrently with the closing of the offering.\nLESL is trading down 1.90% after-hours\nEarlier this month, Leslie's announced a $300M share repurchase program; initiated FY22 guidance","news_type":1},"isVote":1,"tweetType":1,"viewCount":1044,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}